191 related articles for article (PubMed ID: 20203148)
1. Lesion enhancement diminishes with time in primary progressive multiple sclerosis.
Khaleeli Z; Ciccarelli O; Mizskiel K; Altmann D; Miller DH; Thompson AJ
Mult Scler; 2010 Mar; 16(3):317-24. PubMed ID: 20203148
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
3. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.
Bagnato F; Jeffries N; Richert ND; Stone RD; Ohayon JM; McFarland HF; Frank JA
Brain; 2003 Aug; 126(Pt 8):1782-9. PubMed ID: 12821527
[TBL] [Abstract][Full Text] [Related]
4. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Bernardi V; Favaretto A; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P; Filippi M
Neurology; 2009 Apr; 72(15):1330-6. PubMed ID: 19365054
[TBL] [Abstract][Full Text] [Related]
5. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years.
Rovaris M; Judica E; Gallo A; Benedetti B; Sormani MP; Caputo D; Ghezzi A; Montanari E; Bertolotto A; Mancardi G; Bergamaschi R; Martinelli V; Comi G; Filippi M
Brain; 2006 Oct; 129(Pt 10):2628-34. PubMed ID: 16921179
[TBL] [Abstract][Full Text] [Related]
6. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
[TBL] [Abstract][Full Text] [Related]
7. ADC measurements in various patterns of multiple sclerosis lesions.
Phuttharak W; Galassi W; Laopaiboon V; Laopaiboon M; Hesselink JR
J Med Assoc Thai; 2006 Feb; 89(2):196-204. PubMed ID: 16579006
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
9. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis.
Laule C; Vavasour IM; Zhao Y; Traboulsee AL; Oger J; Vavasour JD; Mackay AL; Li DK
Mult Scler; 2010 Jun; 16(6):670-7. PubMed ID: 20558500
[TBL] [Abstract][Full Text] [Related]
10. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
[TBL] [Abstract][Full Text] [Related]
11. The natural history of primary progressive multiple sclerosis.
Koch M; Kingwell E; Rieckmann P; Tremlett H
Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
[TBL] [Abstract][Full Text] [Related]
12. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
Montalban X; Sastre-Garriga J; Filippi M; Khaleeli Z; Téllez N; Vellinga MM; Tur C; Brochet B; Barkhof F; Rovaris M; Miller DH; Polman CH; Rovira A; Thompson AJ
Mult Scler; 2009 Dec; 15(12):1459-65. PubMed ID: 19995843
[TBL] [Abstract][Full Text] [Related]
13. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
[TBL] [Abstract][Full Text] [Related]
14. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
15. A randomized crossover study of bee sting therapy for multiple sclerosis.
Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J
Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950
[TBL] [Abstract][Full Text] [Related]
16. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
[TBL] [Abstract][Full Text] [Related]
17. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis.
Minneboo A; Barkhof F; Polman CH; Uitdehaag BM; Knol DL; Castelijns JA
Arch Neurol; 2004 Feb; 61(2):217-21. PubMed ID: 14967769
[TBL] [Abstract][Full Text] [Related]
18. The natural history of primary progressive MS in British Columbia, Canada.
Tremlett H; Paty D; Devonshire V
Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
[TBL] [Abstract][Full Text] [Related]
19. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
[TBL] [Abstract][Full Text] [Related]
20. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
Molyneux PD; Filippi M; Barkhof F; Gasperini C; Yousry TA; Truyen L; Lai HM; Rocca MA; Moseley IF; Miller DH
Ann Neurol; 1998 Mar; 43(3):332-9. PubMed ID: 9506550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
